Statins linked to lower glaucoma risk and reduced need for surgery

A large analysis of medical records spanning two decades suggests that people taking statins to manage cholesterol may be getting an unexpected benefit: protection against glaucoma, one of the leading causes of irreversible blindness worldwide. The findings, published in the British Journal of Ophthalmology, come from researchers who examined data on more than 420,000 individuals drawn from a global database of 165 million patient records.

Glaucoma develops when the optic nerve sustains permanent damage, typically from elevated pressure inside the eye. It progresses silently in many cases, which is why it remains such a significant public health concern—people often don't realize they have it until vision loss has already occurred. Statins, the cholesterol-lowering drugs prescribed to millions worldwide, have long been suspected of having effects beyond their primary purpose. Laboratory studies have suggested they may slow or prevent the death of nerve cells, but whether this translates to real protection against glaucoma has remained unclear.

To test this possibility, researchers compared two large groups followed between August 2006 and August 2026. One group consisted of 210,000 people with documented statin use; the other, a matched control group of 210,000 people with no record of statin use. Both groups had undergone eye examinations during the study period. After five years, the statin users showed a 15% lower risk of developing open-angle glaucoma, the most common form of the disease. In raw numbers, 4,771 new glaucoma cases appeared in the statin group (2.3% of that population) compared with 5,491 in the control group (2.6%).

The potential benefit extended beyond prevention. In a separate analysis of people who already had glaucoma, those taking statins were significantly less likely to need escalating treatments as their disease progressed. Among more than 30,000 statin users with glaucoma and nearly 250,000 non-users with the same diagnosis, statin use was associated with a 36% lower risk of requiring conventional incisional glaucoma surgery over five years. The reduction was even more pronounced for minimally invasive procedures: a 55% lower risk of minimally invasive glaucoma surgery and a 60% lower risk of selective laser trabeculoplasty, a laser-based procedure that reduces eye pressure. Statin users also showed a 12% reduced need for prescription eye drops to manage pressure. These associations held up even after ten years of follow-up.

The researchers acknowledge significant limitations in their work. This is an observational study, meaning it can show that two things occur together but cannot prove that one causes the other. The researchers did not have access to detailed patient information such as individual eye pressure measurements or specifics about why surgeries were performed—whether because disease had worsened or because a patient had stopped taking prescribed medications. Without such details, it remains impossible to know whether statins themselves are protective or whether statin users differ in some other way that accounts for their better outcomes.

Despite these constraints, the researchers argue their findings add weight to a growing body of evidence suggesting statins may protect nerve tissue from damage. They call for randomized controlled trials—the gold standard of medical research—to determine whether statins actually prevent or slow glaucoma, or whether the association observed in this database study reflects other factors at play. If future trials confirm a causal link, statins could offer a dual benefit to patients managing both high cholesterol and glaucoma risk simultaneously, potentially sparing some people from sight-threatening surgery.